Evidence map›Paper›PMID 38481861›Full record

ArticleTranslational andrology and urology2024

Long noncoding RNA

Mingfei Jia, Xi Chen, Shaosan Kang, Fenghong Cao, Yansheng Zhao, Liguo Zhang, Xinghua Bao, Lei Wang, Hengran Li, Chenggang Li

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational andrology and urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mingfei JiaNorth China Graduate School of University of Science and Technology, Tangshan, China.
Xi ChenDepartment of Urology, North China University of Science and Technology Affiliated Hospital, Tangshan, China.
Shaosan KangDepartment of Urology, North China University of Science and Technology Affiliated Hospital, Tangshan, China.
Fenghong CaoDepartment of Urology, North China University of Science and Technology Affiliated Hospital, Tangshan, China.
Yansheng ZhaoDepartment of Nuclear Magnetic, Kailuan General Hospital, Tangshan, China.
Liguo ZhangDepartment of Urology, North China University of Science and Technology Affiliated Hospital, Tangshan, China.
Xinghua BaoDepartment of Urology, North China University of Science and Technology Affiliated Hospital, Tangshan, China.
Lei WangDepartment of Urology, North China University of Science and Technology Affiliated Hospital, Tangshan, China.
Hengran LiDepartment of Urology, North China University of Science and Technology Affiliated Hospital, Tangshan, China.
Chenggang LiDepartment of Urology, ZunHua People's Hospital, Tangshan, China.
North China University of Science and Technology Affiliated Hospital · CNKailuan General Hospital · CNNorth China University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Clear cell renal cell carcinoma (RCC) is the most common subtype of RCC. Although targeted therapy can provide superior treatment outcomes, it is prone to drug resistance, and individual responses to immunotherapy vary greatly. Therefore, finding new diagnostic and therapeutic targets for RCC is of considerable importance. Long noncoding RNA (lncRNA) Methods: Small interfering RNA (siRNA) and plasmid cloning DNA (pcDNA) 3.1 were used to transfect renal cancer cell line 786-0 to silence and overexpress the lncRNA Results: Compared with blank control group and negative control group, the siGPRC5D-AS1 group showed a significant decrease in the relative expression of lncRNA Conclusions: Silencing the expression of lncRNA

Indexed as

invasionLong noncoding RNA GPRC5D-AS1 (lncRNA GPRC5D-AS1)migrationproliferationrenal cancer cell line 786-0

Identifiers

PMID38481861
PMCPMC10932641
OpenAlexW4392202745

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.